These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38819023)

  • 1. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.
    Markova L; Maji M; Kostrhunova H; Novohradsky V; Kasparkova J; Gibson D; Brabec V
    J Med Chem; 2024 Jun; 67(11):9745-9758. PubMed ID: 38819023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
    J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
    Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative mechanism of action of the DNP Pt
    Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
    Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
    Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
    Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum(IV) Complexes of
    Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
    Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z; Hu W; Wang Z; Gou S
    Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
    Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
    Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
    Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X; Fang L; Zhao J; Gou S
    Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
    Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
    J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.